← Back
$DAWN All transactions

Day One Biopharmaceuticals, Inc.

D

$ Value

Shares

4,397

Price

Filed

Apr 23

Insider

Name

VASCONCELLES MICHAEL

Title

Head of Research and Dev.

CIK

0001734755

Roles

Officer

Transaction Details

Transaction Date

2026-04-23

Code

D

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

Footnotes

On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. | Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. | The option vests as to 1/4th of the total grant on June 16, 2026, and 1/48th of the total grant will vest on each monthly anniversary thereafter, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. | Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. | The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. | The RSUs vest as to 25% of the total award on August 15, 2026, and 1/12th of the remaining RSUs vest in quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each RSU vesting date. | RSUs do not expire; they either vest or are canceled prior to the RSU vesting date. | The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing Info

Accession No.

0001734755-26-000005

Form Type

4

Issuer CIK

0001845337

VASCONCELLES MICHAEL's History

Date Ticker Type Value
2026-04-23 DAWN D
2026-04-23 DAWN D
2026-04-23 DAWN D
2026-04-23 DAWN D
2026-04-23 DAWN D
2026-02-17 DAWN $32K
2026-02-15 DAWN M
2026-02-15 DAWN M $0
2026-01-30 DAWN A $0
2026-01-30 DAWN A $0

Other Insiders at DAWN (90d)

Insider Bought Sold Last
Garland J. Scott 2026-04-23
Ramasastry Saira 2026-04-23
Holles Natalie C. 2026-04-23
Nicholson Garry A 2026-04-23
York Charles N II
COO and CFO
$70K 2026-04-23
Dable Habib J 2026-04-23
Grossman William 2026-04-23
VASCONCELLES MICHAEL
Head of Research and Dev.
$32K 2026-04-23
Dubow Adam
Gen Counsel & Secretary
$74K 2026-04-23
Josey John A. 2026-04-23
Merendino Lauren
Chief Commercial Officer
$67K 2026-04-23
Bender Jeremy
CHIEF EXECUTIVE OFFICER
$179K 2026-04-23